scPharmaceuticals
The business, the turning points, and the decisions behind them.
Some sections are still being researched2 / 4
Sections to complete：02 · 05
01 / WHAT IT BUILT
What the company did
scPharmaceuticals was a Burlington, Massachusetts pharmaceutical company (Nasdaq: SCPH) founded in 2013 and led by CEO John Tucker, focused on optimizing infused therapies into subcutaneous products. Its commercial franchise was built around FUROSCIX — the first self-administered subcutaneous loop diuretic, an 80-mg furosemide formulation delivered via an on-body infusor for outpatient treatment of congestion due to fluid overload in chronic heart failure and chronic kidney disease, launched in February 2023. The pipeline also included SCP-111, a pH-neutral aqueous furosemide formulation for subcutaneous injection, and an SCP-111 autoinjector program. FUROSCIX generated $27.8 million in net sales in the first half of 2025, up 96% year over year.
02 / FAILURE REASONS
Material for this section is being gathered and checked. It will appear here once ready.
03 / EVENT HISTORY
Events in the structured record
- Company founded
scPharmaceuticals is founded in Massachusetts as a Delaware LLC (converted to a corporation in 2014).
- IPO
The company goes public on Nasdaq under the symbol SCPH.
- FUROSCIX launch
FUROSCIX launches commercially in February 2023 as the first self-administered subcutaneous loop diuretic.
- MannKind acquisition
In August 2025, MannKind agrees to acquire scPharmaceuticals for $5.35 cash per share plus up to $1.00 in contingent value rights; the deal closes October 7, 2025 and the stock is delisted from Nasdaq.
04 / CONTEMPORARY REBUILD ASSESSMENT
Difficulty of rebuilding this project today
Material for this section is being gathered and checked. It will appear here once ready.
Overall assessment: Not completed
05 / CAUSAL CHAIN / AFTERMATH
Material for this section is being gathered and checked. It will appear here once ready.